DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228.

MLA

Fiorentino, Francesca, et al. “DICE: Dual MTorc Inhibition in AdvanCed/Recurrent Epithelial Ovarian Cancer Resistant to Standard Treatment-a Study Protocol for a Randomised Trial Investigating a Novel Therapy Called TAK228.” Trials, vol. 23, no. 1, Apr. 2022, pp. 1–15. EBSCOhost, https://doi.org/10.1186/s13063-022-06201-3.

APA

Fiorentino, F., Krell, J., de la Rosa, C. N., & Webber, L. (2022). DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228. Trials, 23(1), 1–15. https://doi.org/10.1186/s13063-022-06201-3

Chicago

Fiorentino, Francesca, Jonathan Krell, Consuelo Nohpal de la Rosa, and Lee Webber. 2022. “DICE: Dual MTorc Inhibition in AdvanCed/Recurrent Epithelial Ovarian Cancer Resistant to Standard Treatment-a Study Protocol for a Randomised Trial Investigating a Novel Therapy Called TAK228.” Trials 23 (1): 1–15. doi:10.1186/s13063-022-06201-3.